Important: VAERS reports alone cannot determine if a vaccine caused an adverse event. Reports may contain incomplete, inaccurate, or unverified information. Correlation does not equal causation.
H5N1 avian influenza has been circulating in U.S. dairy cattle and poultry flocks since early 2024, with sporadic human cases raising pandemic preparedness concerns. Multiple vaccine candidates are in development or already stockpiled. Here is where things stand heading into mid-2026.
In March 2024, USDA confirmed the first detection of highly pathogenic avian influenza (HPAI) H5N1 in U.S. dairy cattle — an unprecedented finding that upended assumptions about which mammals could sustain the virus. By mid-2026, the outbreak has spread to over 940 dairy herds across more than 30 states, affected hundreds of millions of poultry (driving egg prices to record highs), and been detected in cats, raccoons, bears, and marine mammals.
Globally, the H5N1 clade 2.3.4.4b has become the dominant circulating strain, reported in 87 countries across six continents. Wild bird migration continues to seed new outbreaks, making eradication virtually impossible. The question is no longer whether the virus will persist, but whether it will adapt to spread efficiently between humans.
As of July 2026, the CDC has confirmed 73 human H5N1 cases in the United States. The majority have occurred among dairy farm workers and poultry workers with direct occupational exposure to infected animals. Most cases presented with conjunctivitis (eye infection) or mild upper respiratory symptoms. However, several cases required hospitalization, and one death was reported in January 2025 — a Louisiana resident with significant underlying health conditions.
Crucially, no sustained human-to-human transmission has been documented. Every confirmed U.S. case has been traced to direct animal contact, though a small number of household contacts developed symptoms that could not be definitively linked to independent animal exposure, keeping epidemiologists vigilant.
Several pharmaceutical companies have H5N1 vaccine candidates at various stages of development and regulatory review:
The U.S. government maintains a stockpile of pre-pandemic H5N1 vaccine as part of its pandemic preparedness strategy. As of 2026, ASPR (Administration for Strategic Preparedness and Response) reports approximately 10,000,000 doses of H5N1 vaccine in bulk antigen and finished form, plus separate stockpiles of MF59 and AS03 adjuvants that can stretch dose counts significantly — a technique called "dose-sparing" that was validated during the 2009 H1N1 pandemic.
However, 10,000,000 doses would cover only a fraction of the U.S. population of 340 million. In a pandemic scenario, vaccine manufacturing would need to scale rapidly, which is why BARDA has invested in "warm base" manufacturing capacity — keeping production lines ready to pivot from seasonal flu to pandemic flu vaccine on short notice. The estimated timeline from pandemic declaration to first public doses is 12–16 weeks for egg-based vaccines and potentially faster for mRNA platforms.
The FDA has a unique regulatory pathway for pre-pandemic influenza vaccines. These vaccines are approved based on immunogenicity (their ability to generate an immune response) rather than real-world efficacy against disease, since it is not possible to run a traditional efficacy trial before a pandemic starts. This framework allows vaccines to be manufactured and stockpiled in advance, then deployed under their existing approval (potentially with a strain update) once a pandemic is declared.
CSL Seqirus' adjuvanted H5N1 vaccine and Sanofi's earlier H5N1 candidate have both received FDA pre-pandemic approval. In a pandemic scenario, these could be distributed without needing a new Emergency Use Authorization, though the FDA would likely require updated clinical data if the circulating strain has drifted significantly from the vaccine antigen.
Across multiple candidates, clinical trial data for H5N1 vaccines shows consistent findings:
The World Health Organization maintains a global influenza surveillance network that monitors H5N1 evolution in real time. WHO's Global Influenza Surveillance and Response System (GISRS) regularly updates candidate vaccine viruses — standardized reference strains that manufacturers use to produce vaccines. As of 2026, WHO has issued updated CVVs for the clade 2.3.4.4b viruses circulating in North American cattle and poultry.
WHO has also coordinated advance purchase agreements with several manufacturers to ensure that low- and middle-income countries would have access to pandemic vaccines, addressing equity gaps exposed during the COVID-19 pandemic. The organization estimates that global manufacturing capacity for pandemic influenza vaccine has roughly doubled since 2019, to approximately 8 billion doses per year across all platforms.
If an H5N1 vaccine is deployed to the public, safety monitoring would follow the enhanced framework established during COVID-19 vaccination. This includes VAERS for passive adverse event reporting, the Vaccine Safety Datalink (VSD) for active near-real-time surveillance in large health systems, V-safe for participant-reported outcomes via smartphone, and the Clinical Immunization Safety Assessment (CISA) Project for complex case evaluation.
VaccineWatch would track VAERS reports for any authorized H5N1 vaccine, providing the same transparent data exploration available for seasonal flu vaccines and other immunizations. Given the lessons learned from COVID-19 vaccine safety monitoring, the infrastructure is substantially more mature than it was in 2020.
Current seasonal flu vaccines do not protect against H5N1. Seasonal vaccines target H1N1, H3N2, and influenza B strains — the subtypes circulating in humans. H5N1 is antigenically distinct, requiring a dedicated vaccine. However, the manufacturing infrastructure overlaps significantly: the same egg-based and cell-based production facilities used for seasonal flu can be repurposed for pandemic H5N1 vaccine production, though this would likely disrupt seasonal flu vaccine supply.
This tradeoff is one reason mRNA platforms are seen as strategically valuable — they use entirely separate manufacturing processes and would not compete with seasonal flu production capacity.
H5N1 has not become a pandemic, and the current risk to the general public remains low. But the virus's unprecedented spread through U.S. dairy cattle, continued poultry outbreaks, and sporadic human infections have elevated preparedness planning to a level not seen since the early days of COVID-19. Multiple vaccine candidates are ready or nearly ready for rapid deployment, the stockpile provides a first-wave buffer, and surveillance systems are in place to monitor safety if vaccination begins. The situation bears watching — and VaccineWatch will track any H5N1 vaccine VAERS data as it becomes available.